1. A7.17 Effects of baricitinib on multibiomarker disease activity scores and their components in a phase 2b study in moderate-to-severe rheumatoid arthritis patients. (24th February 2016) Authors: Taylor, PC; Genovese, MC; Keystone, E; Weinblatt, M; Rancourt, J; Nantz, E; Schlichting, DE; Zuckerman, SH; Macias, WL Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 1 Page Start: A62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0207 Change in anti-citrullinated protein autoantibody levels in clinical practice are associated with resource use and disease activity measures. (15th June 2017) Authors: Alemao, E; Guo, Z; Iannaccone, C; Frits, M; Shadick, N; Weinblatt, M Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0239 Results of a phase 2b study of vobarilizumab, an anti-interleukin-6 receptor nanobody, as monotherapy in patients with moderate to severe rheumatoid arthritis. (15th June 2017) Authors: Dörner, T; Weinblatt, M; Beneden, K Van; Dombrecht, EJ; Beuf, K De; Schoen, P; Zeldin, RK Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 575 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP0098 Remission and maintenance of efficacy in a phase 2b study of vobarilizumab, an anti-interleukin 6 receptor nanobody, in patients with moderate-to-severe rheumatoid arthritis despite treatment with methotrexate. (15th June 2017) Authors: Dörner, T; Weinblatt, M; Durez, P; Alten, R; Beneden, K Van; Dombrecht, EJ; Beuf, K De; Schoen, P; Zeldin, RK Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP0203 Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an adalimumab biosimilar) with reference adalimumab in patients with rheumatoid arthritis. (15th June 2017) Authors: Kay, J; Weinblatt, M; Keystone, E; Genovese, M; Ghil, J; Cheong, SY; Hong, EE Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Issue 10 (12th September 2008) Authors: Aletaha, D; Landewe, R; Karonitsch, T; Bathon, J; Boers, M; Bombardier, C; Bombardieri, S; Choi, H; Combe, B; Dougados, M; Emery, P; Gomez-Reino, J; Keystone, E; Koch, G; Kvien, T K; Martin-Mola, E; Matucci-Cerinic, M; Michaud, K; O'Dell, J; Paulus, H Journal: Annals of the rheumatic diseases Issue: Volume 67:Issue 10(2008) Page Start: 1360 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. SAT0041 Efficacy of abatacept versus adalimumab in patients with seropositive, erosive early ra: analysis of a randomized controlled clinical trial (AMPLE). (15th June 2017) Authors: Fleischmann, R; Weinblatt, M; Ahmad, H; Maldonado, M; Alemao, E; Ye, J; Schiff, M Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 782 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. SAT0197 Treatment outcomes with anti-tnf and non-anti-tnf disease-modifying therapy by baseline body mass index. (15th June 2017) Authors: Alemao, E; Guo, Z; Iannaccone, C; Frits, M; Weinblatt, M; Shadick, N Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 846 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region. Issue 1 (28th April 2015) Authors: Mariette, X; Vencovsky, J; Lortholary, O; Gomez-Reino, J; de Longueville, M; Ralston, P; Weinblatt, M; van Vollenhoven, R Journal: RMD open Issue: Volume 1:Issue 1(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗